A5010618143- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Childhood Cancer Survivors' Quality of Life
- Advances in Oncology and Radiotherapy
- Cancer therapeutics and mechanisms
- Respiratory Support and Mechanisms
- COVID-19 and healthcare impacts
- Pharmacological Receptor Mechanisms and Effects
- Brain Metastases and Treatment
- Neurofibromatosis and Schwannoma Cases
- Acute Lymphoblastic Leukemia research
- Ethics and Legal Issues in Pediatric Healthcare
- Cancer Genomics and Diagnostics
- Vagus Nerve Stimulation Research
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Renal and related cancers
- Management of metastatic bone disease
- Tumors and Oncological Cases
- Glioma Diagnosis and Treatment
- Global Cancer Incidence and Screening
- COVID-19 Clinical Research Studies
Hospital Sant Joan de Déu Barcelona
2019-2024
Universitat de Barcelona
2024
Naxitamab is an anti-GD2 antibody approved for the treatment of relapsed/refractory HR-NB. We report survival, safety, and relapse pattern a unique set HR-NB patients consolidated with naxitamab after having achieved first CR. Eighty-two were treated 5 cycles GM-CSF days at 250 μg/m2/day (-4 to 0), followed by 500 (1-5) 3 mg/kg/day (1, 3, 5), on outpatient basis. All but one older than 18 months diagnosis had stage M; 21 (25.6%) pts MYCN-amplified (A) NB; 12 (14.6%) detectable MRD in BM....
Patients with high-risk neuroblastoma (HR-NB) who are unable to achieve a complete response (CR) induction therapy have worse outcomes. We investigated the combination of humanized anti-GD2 mAb naxitamab (Hu3F8), irinotecan (I), temozolomide (T), and sargramostim (GM-CSF)-HITS-against primary resistant HR-NB. Eligibility criteria included having measurable chemo-resistant disease at end (EOI) treatment. were excluded if they had progressive (PD) during induction. Prior and/or I/T was...
Naxitamab is a humanized anti-disialoganglioside (GD2) monoclonal antibody approved for treatment of bone/bone marrow refractory high-risk neuroblastoma (HR-NB). Compassionate use (CU) expanded access program at Hospital Sant Joan de Deu permitted patients in complete remission (CR). We here report the survival, toxicity, and relapse pattern first or second CR treated with naxitamab sargramostim (GM-CSF).Seventy-three consecutive HR-NB (stage M age >18 months MYCN-amplified stages L1/L2 any...
Background: Treatment of HR-NB comprise induction, consolidation with autologous stem cell transplant (ASCT) followed by anti-GD2 immunotherapy and isotretinoin. Childrens Oncology Group SIOPEN studies used dinutuximab cytokines to treat patients in complete remission or refractory Bone/Bone marrow (B/BM) disease after ASCT. Methods: referred Hospital Sant Joan de Déu for were eligible two consecutive (dinutuximab EudraCT 2013–004864–69 naxitamab 017–001829–40) naxitamab/Sargramostim CU...
Abstract The goals of this work were to identify factors favoring patient‐derived xenograft (PDX) engraftment and study the association between PDX prognosis in pediatric patients with Ewing sarcoma, osteosarcoma, rhabdomyosarcoma. We used immunodeficient mice establish 30 subcutaneous from patient tumor biopsies, a successful rate 44%. Age greater than 12 years relapsed disease associated higher rate. Tumor type biopsy location did not associate engraftment. models retained histology...
Latin American countries are improving childhood cancer care, showing strong commitment to implement the Global Initiative for Childhood Cancer, but there scant publications of situation at a continental level.
Abstract Background Wilms tumour (WT) is one of the cancer types targeted by Global Initiative for Childhood Cancer (GICC). The objective this study was to describe outcomes Africa Phase II in sub‐Saharan Africa. Methods used a comprehensive WT treatment protocol multi‐centre, prospective conducted eight hospitals Ethiopia (2), Ghana Malawi, Cameroon, Zimbabwe and Uganda. Eligibility criteria were: age younger than 16 years, unilateral WT, diagnosed between 1 January 2021 31 December 2022....
Introduction Anti-disialoganglioside 2 (anti-GD2) monoclonal antibodies (mAbs) are associated with Grade ≥3 (≥G3) adverse events (AEs) such as severe pain, hypotension, and bronchospasm. We developed a novel method of administering the GD2-binding mAb naxitamab, termed “Step-Up” infusion (STU), to reduce risk AEs Methods Forty-two patients GD2-positive tumors received naxitamab under “compassionate use” protocols administered via either standard regimen (SIR) or STU regimen. The SIR...
Background: Neuroblastic tumors (NBTs) originate from a block in the process of differentiation. Histologically, NBTs are classified neuroblastoma (NB), ganglioneuroblastoma (GNB), and ganglioneuroma (GN). Current therapy for high-risk (HR) NB includes chemotherapy, surgery, radiotherapy, anti-GD2 monoclonal antibodies (mAbs). Anti-GD2 mAbs induce immunological cytoxicity but also direct cell death. Methods: We report on patients treated with naxitamab chemorefractory showing lesions long...
Neuroblastoma presents with two patterns of disease: locoregional or systemic. The poor prognostic risk factors neuroblastoma (LR-NB) include age, MYCN MDM2-CDK4 amplification, 11q, histology, diploidy ALK TERT mutations, and ATRX aberrations. Anti-GD2 immunotherapy has significantly improved the outcome high-risk (HR) NB is mostly effective against osteomedullary minimal residual disease (MRD), but less so soft tissue disease. question whether adding anti-GD2 monoclonal antibodies (mAbs)...
10028 Background: Chemoresistant disease is an obstacle for cure of high-risk neuroblastoma (HR-NB). Anti-GD2 monoclonal antibodies (MoAb) dinutuximab and naxitamab in combination with cytokines are FDA-approved to consolidate remission chemorefractory osteomedullary HR-NB, but responses progressive (PD) rare. We investigated the Humanized anti-GD2 MoAb (Hu3F8), Irinotecan, Temozolomide Sargramostim (GMCSF) a phase II "HITS" protocol against resistant HR-NB (NCT03189706). Noteworthy...
10025 Background: Chemoresistant and relapsed disease are major obstacles to curing high-risk neuroblastoma (HR-NB). Anti-GD2 monoclonal antibody (MoAb) is effective in preventing relapse after remission but responses or progressive (PD) rare. We investigated the combination of humanized anti-GD2 MoAb naxitamab, (previously termed Hu3F8), irinotecan, temozolomide sargramostim (GM-CSF): a pilot HITS protocol against resistant HR-NB now expanded phase II study (NCT03189706). Methods: Salient...
The International Society of Paediatric Oncology (SIOP) launched a program to map all pediatric cancer facilities around the world. After results in Africa were completed, strategy for data collection Latin America was revised improve accuracy and avoid duplications. In partnership with SIOP, Sociedad Latino Americana de Oncología Pediátrica (SLAOP) approached their delegates who provided contacts 10-question survey about institutional capacities. Data collected by email, online meetings, or...
Background Anti-GD2 monoclonal antibodies (mAbs) have shown to improve the overall survival of patients with high-risk neuroblastoma (HR-NB). Serious adverse events (AEs), including pain, within hours antibody infusion, limited development these therapies. In this study, we provide evidence Autonomic Nervous System (ANS) activation as mechanism explain main side effects anti-GD2 mAbs. Methods Through confocal microscopy and computational super-resolution experiments explored GD2 expression...
10037 Background: Patients with relapsed/refractory (R/R) high-risk neuroblastoma (HR-NB) have dismal prognosis chemotherapy-only salvage regimens. Naxitamab, a humanized anti-GD2 monoclonal antibody (mAb), when combined Irinotecan and Temozolomide (I/T), has demonstrated clinically meaningful efficacy in R/R HR-NB patients (NCT03189706). We aimed to investigate the potential synergy of naxitamab other cytotoxics. Methods: In this retrospective analysis, we examined treated at SJD...
Abstract The TeLeo Program offers a free‐access 2‐year online learning program to support fellowship programs in pediatric oncology, enhance networking opportunities, and facilitate the exchange of context‐specific, educational content within oncology community training Latin America. In its first edition beginning 2021, 185 fellows from 40 centers 12 American countries were enrolled. Additional courses for other healthcare professionals related region produced further program. A digital...
Introduction: High-risk neuroblastoma, particularly in the relapse/refractory (R/R) setting, poses unique challenges to obtaining representative-quality tissue that is mostly required for molecular analysis. This study explores use of 123I-MIBG radioguided surgery access complex locations MIBG-positive neuroblastoma as a tool overcome difficulties associated with repeated surgeries these patients. Methods: retrospective review all patients R/R and MIBG-uptaking lesions who underwent between...
Introduction: Since the beginning of SARS-CoV-2 pandemic, it has been widely recognized that children and adolescents seem to have milder clinical courses as compared adult counterparts. However, there is concern vulnerable collectives including pediatric patients treated for cancer or under immunosuppression may be at higher risk.Aim Methods: We retrospectively collected Spanish COVID-19 cases in with solid hematological malignancies, non-malignant chronic hematologic conditions , post...
e14502 Background: Intravenous administration of anti-ganglioside GD2 monoclonal antibodies (mAbs) is commonly associated with adverse events (AEs) such as pain and hypertension. Naxitamab an anti-GD2 mAb intended for outpatient use a short (30-60 minutes) time 60%-70% patients in clinical studies experiencing grade 3-4 or hypotension. To reduce this risk we assessed novel protocol (StU) that modulates the pharmacodynamics (PD) naxitamab mitigates infusion-related reactions. Methods:...
10539 Background: Treatment of high-risk NB within the major international cooperative groups (COG and SIOP) comprise intensive induction, consolidation with high dose chemotherapy autologous stem cell rescue (ASCR) followed by anti-GD2 immunotherapy isotretinoin as maintenance therapy. In COG studies dinutuximab cytokines (GM-CSF IL-2) were used to treat patients in complete remission (CR) after ASCR whereas SIOPEN dinutuximab-beta plus/minus IL-2 included responsive (no progression 109...
Background: Since the beginning of SARS-CoV-2 pandemic, it has been widely recognized that children and adolescents seem to have milder clinical courses as compared adult counterparts. However, there is concern vulnerable collectives including pediatric patients treated for cancer or under immunosuppression may be at higher risk. Methods: We retrospectively collected Spanish COVID-19 cases in with solid hematological malignancies, non-malignant chronic hematologic conditions, post...